Ragini R. Kudchadkar
Experienced in Hairy Cell Leukemia (HCL)

Dr. Ragini R. Kudchadkar

Oncology
1365 Clifton Rd Ne, 2nd Floor, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Hairy Cell Leukemia (HCL)
1365 Clifton Rd Ne, 2nd Floor, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ragini Kudchadkar is an Oncologist in Atlanta, Georgia. Dr. Kudchadkar is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Basal Cell Skin Cancer, and Melanoma of the Eye.

Her clinical research consists of co-authoring 102 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles and participated in 1 clinical trial in the study of Hairy Cell Leukemia (HCL).

Specialties
Oncology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

1365 Clifton Rd Ne, 2nd Floor, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Pilot Study of Neoadjuvant/Adjuvant Cemiplimab for High Risk Cutaneous Squamous Cell Carcinoma
Enrollment Status: Recruiting
Publish Date: August 14, 2025
Intervention Type: Radiation, Biological, Procedure
Study Drug: Cemiplimab
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER)
Enrollment Status: Recruiting
Publish Date: June 20, 2024
Intervention Type: Drug
Study Drugs: TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel
Study Phase: Phase 1
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Other, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2025
Intervention Type: Drug, Other
Study Phase: Phase 2
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2025
Intervention Type: Drug
Study Phase: Phase 2
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Phase 1 Study of IMC-CS4, a Monoclonal Antibody Targeted to the CSF-1 Receptor (CSF-1R), In Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy is Available
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Biological
Study Phase: Phase 1
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: June 26, 2024
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Other, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

102 Total Publications

HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors.
Journal: Future oncology (London, England)
Published: October 15, 2025
Similar Doctors
Advanced in Hairy Cell Leukemia (HCL)
Dr. Jeffrey A. Thomas
Hematology Oncology | Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Jeffrey A. Thomas
Hematology Oncology | Hematology | Oncology

University Cancer And Blood Center, LLC

3320 Old Jefferson Rd, Bldg 700, 
Athens, GA 
 (53.5 miles away)
706-353-2990
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Thomas is a Hematologist Oncology specialist and a Hematologist in Athens, Georgia. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Midline Lethal Granuloma, Iron Deficiency Anemia, Essential Thrombocythemia, and Breast Cancer. Dr. Thomas is currently accepting new patients.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Stephen M. Szabo
Hematology Oncology | Hematology | Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Stephen M. Szabo
Hematology Oncology | Hematology | Oncology

Piedmont Providers LLC

1412 Milstead Ave Ne, 
Conyers, GA 
 (19.9 miles away)
404-367-3558
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Stephen Szabo is a Hematologist Oncology specialist and a Hematologist in Conyers, Georgia. Dr. Szabo is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hereditary Neuroblastoma, Inflammatory Breast Cancer, Gastric Lymphoma, Bone Marrow Aspiration, and Colonoscopy. Dr. Szabo is currently accepting new patients.

Advanced in Hairy Cell Leukemia (HCL)
Dr. Shyam L. Khanwani
Oncology
Advanced in Hairy Cell Leukemia (HCL)
Dr. Shyam L. Khanwani
Oncology

Nsh Cancer Institute Professional Services G LLC

132 Old Norton Rd, Suite 200, 
Fayetteville, GA 
 (25.9 miles away)
678-817-1117
Experience:
34+ years
Languages Spoken:
English, Hindi, Urdu
See accepted insurances
Offers Telehealth

Shyam Khanwani is an Oncologist in Fayetteville, Georgia. Dr. Khanwani has been practicing medicine for over 34 years and is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Childhood Iron Deficiency Anemia, and Iron Deficiency Anemia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kudchadkar's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 49 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile